Try our beta test site

Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Northwestern University Identifier:
First received: December 10, 1999
Last updated: May 31, 2012
Last verified: May 2012

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: Phase III trial to study the effectiveness of melphalan followed by peripheral stem cell transplantation in treating patients who have multiple myeloma.

Condition Intervention Phase
Multiple Myeloma and Plasma Cell Neoplasm
Biological: filgrastim
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Northwestern University:

Study Start Date: October 1999
Study Completion Date: August 2003
Primary Completion Date: August 2003 (Final data collection date for primary outcome measure)
Detailed Description:


  • Administer standard, high dose melphalan safely in a closely monitored setting in patients with responsive multiple myeloma.
  • Determine the cost and time effectiveness in the collection of sufficient peripheral blood stem cells (PBSC) for two high dose melphalan therapies and PBSC transplantations in this patient population.

OUTLINE: Patients not in remission receive 3-6 courses of remission induction therapy consisting of either an anthracycline/glucocorticoid regimen or high dose glucocorticoids.

At 21-45 days following induction therapy, patients receive filgrastim (G-CSF) subcutaneously daily for 4 days followed by daily peripheral blood stem cell (PBSC) collection beginning on day 4 and continuing until the target number of cells is reached.

At 5 days to 6 weeks following PBSC collection, patients receive high dose melphalan IV over 2 hours for 2 consecutive days. At 36-48 hours following completion of melphalan, patients receive infusion of PBSC followed by G-CSF subcutaneously daily until blood counts recover.

At 3 months to 5 years following high dose therapy and PBSC infusion, patients with evidence of disease progression receive an additional treatment with high dose melphalan followed by PBSC infusion as in the first course.

Patients are followed at 30-45 days, 6 months, and then annually thereafter.

PROJECTED ACCRUAL: A total of 60-120 patients will be accrued for this study over 5 years.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosed active multiple myeloma defined by:

    • Lytic disease
    • Anemia
    • Hypercalcemia
    • Secondary renal insufficiency
    • More than 400 mg/24 hours of urinary protein excretion
    • Symptomatic hyperviscosity
  • If previously treated, refractory to no more than 1 regimen
  • Primary amyloidosis without subsequent multiple myeloma allowed

    • Abnormal renal function allowed if due to primary disease



  • Not specified

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • See Disease Characteristics
  • Creatinine clearance greater than 50 mL/min if no renal impairment


  • No cardiac function that would preclude study
  • LVEF greater than 45%


  • No pulmonary function that would preclude study
  • FVC greater than 60% predicted
  • DLCO greater than 50% predicted


  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy

  • Not specified


  • No greater than 18 months of prior alkylator exposure

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified


  • See Disease Characteristics
  • No more than 3 prior treatment regimens allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004165

United States, Illinois
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
National Cancer Institute (NCI)
Study Chair: Ann Traynor, MD Robert H. Lurie Cancer Center
  More Information

Responsible Party: Northwestern University Identifier: NCT00004165     History of Changes
Other Study ID Numbers: NU 97H6T
Study First Received: December 10, 1999
Last Updated: May 31, 2012

Keywords provided by Northwestern University:
refractory multiple myeloma
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
primary systemic amyloidosis

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on March 30, 2017